Vera Therapeutics Inc - Class A — Quarterly Financial Statistics (NASDAQ:VERA) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Cash from operating activities 36.88 M39.18 M54.41 M54.8 M61.91 M69.99 M 241.1 M Cash from investing activities -38.32 M221.38 M15.32 M28.54 M69.76 M80.66 M 194.29 M Cash from financing activities 739 K325.95 M1.53 M20.29 M797 K286.28 M 308.9 M Free cash flow 36.65 M38.54 M54.22 M54.59 M61.77 M69.89 M 240.47 M

뉴스

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

VeraDermics is said to draw IPO anchor order from Eli Lilly - Bloomberg

베라 테라퓨틱스, Matt Skelton을 최고 상업 책임자로 승진 임명

Vera Therapeutics promotes Matt Skelton to chief commercial officer

JP모건, 베라 테라퓨틱스에 ’비중확대’ 투자의견 유지

JPMorgan reiterates Overweight rating on Vera Therapeutics stock

칸토어 피츠제럴드, 베라 테라퓨틱스에 ’비중확대’ 투자의견 유지

Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock

Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High?

Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

베라 테라퓨틱스, FDA의 아타시셉트 우선 심사 승인 후 주가 상승

Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review